MX2024009163A - Sintesis de un inhibidor de kif18a. - Google Patents

Sintesis de un inhibidor de kif18a.

Info

Publication number
MX2024009163A
MX2024009163A MX2024009163A MX2024009163A MX2024009163A MX 2024009163 A MX2024009163 A MX 2024009163A MX 2024009163 A MX2024009163 A MX 2024009163A MX 2024009163 A MX2024009163 A MX 2024009163A MX 2024009163 A MX2024009163 A MX 2024009163A
Authority
MX
Mexico
Prior art keywords
compound
kif18a
inhibitor
synthesis
salt
Prior art date
Application number
MX2024009163A
Other languages
English (en)
Spanish (es)
Inventor
Sebastien Caille
Daniel Gerard Greene
Michael Thomas Corbett
Carolyn Wei
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2024009163A publication Critical patent/MX2024009163A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02Sulfinic acids; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20Spiro-condensed ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F3/00Compounds containing elements of Groups 2 or 12 of the Periodic Table
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
MX2024009163A 2022-01-26 2023-01-26 Sintesis de un inhibidor de kif18a. MX2024009163A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263303470P 2022-01-26 2022-01-26
PCT/US2023/011636 WO2023146973A1 (en) 2022-01-26 2023-01-26 Synthesis of a kif18a inhibitor

Publications (1)

Publication Number Publication Date
MX2024009163A true MX2024009163A (es) 2024-08-09

Family

ID=85328813

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009163A MX2024009163A (es) 2022-01-26 2023-01-26 Sintesis de un inhibidor de kif18a.

Country Status (12)

Country Link
US (1) US20250129050A1 (enExample)
EP (1) EP4469437A1 (enExample)
JP (1) JP2025505892A (enExample)
KR (1) KR20240144140A (enExample)
CN (1) CN118922406A (enExample)
AR (1) AR128353A1 (enExample)
AU (1) AU2023211589A1 (enExample)
CA (1) CA3248925A1 (enExample)
IL (1) IL314221A (enExample)
MX (1) MX2024009163A (enExample)
TW (1) TW202342451A (enExample)
WO (1) WO2023146973A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211475A1 (es) 2018-12-20 2021-08-05 Amgen Inc Inhibidores de kif18a
WO2024039829A1 (en) 2022-08-18 2024-02-22 Accent Therapeutics, Inc. Inhibitors of kif18a and uses thereof
CN115925589A (zh) * 2022-12-26 2023-04-07 诚达药业股份有限公司 一种脂肪族亚磺酸钙盐及其制备方法
WO2025036479A1 (zh) * 2023-08-16 2025-02-20 上海湃隆生物科技有限公司 驱动蛋白kif18a抑制剂及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211475A1 (es) * 2018-12-20 2021-08-05 Amgen Inc Inhibidores de kif18a
TW202203919A (zh) * 2020-04-14 2022-02-01 美商安進公司 用於治療贅生性疾病之kif18a抑制劑

Also Published As

Publication number Publication date
AR128353A1 (es) 2024-04-24
CN118922406A (zh) 2024-11-08
CA3248925A1 (en) 2023-08-03
KR20240144140A (ko) 2024-10-02
AU2023211589A1 (en) 2024-07-25
WO2023146973A1 (en) 2023-08-03
EP4469437A1 (en) 2024-12-04
IL314221A (en) 2024-09-01
US20250129050A1 (en) 2025-04-24
JP2025505892A (ja) 2025-03-03
TW202342451A (zh) 2023-11-01

Similar Documents

Publication Publication Date Title
AR128353A1 (es) Síntesis de un inhibidor de kif18a
AR117101A1 (es) Síntesis mejorada del intermedio clave del compuesto inhibidor de g12c de kras
CO2023014807A2 (es) Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras
MX2022010795A (es) Hidrato cristalino de un compuesto inhibidor de jak.
PE20231938A1 (es) Inhibidores de cdk y metodos de uso de estos
CL2024003354A1 (es) Compuesto cíclico que tiene acción inhibitoria selectiva sobre kras por encima de hras y nras
CL2021000737A1 (es) Fabricación de compuestos y composiciones para inhibir la actividad de shp2
CO6400227A2 (es) Análogos de nucleosidos
CL2020001871A1 (es) Dihidrobenzofurano e inden analogos como inhibidores de sarcómero cardíaco.
CO2024001367A2 (es) Compuestos antivirales
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
DOP2025000087A (es) Compuestos tricíclicos y sus usos
CY1111481T1 (el) Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης
AR069798A1 (es) Derivados de 1, 3-tiazol, metodos para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de medicamentos para el tratamiento de enfermedades mediadas por la fosfatidilinositol 3-cinasa.
CY1114689T1 (el) C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης
MXPA04002993A (es) Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios.
MX2024012348A (es) Forma cristalina de lanifibranor
AR124694A1 (es) Hidrato cristalino de sal de sodio de topramezona novedoso y método de preparación del mismo
CO2024013702A2 (es) Derivados de pirido-[3,4-d]piridazina amina útiles como derivados de nlrp3
CL2021002575A1 (es) Compuestos de pirrol
EA201290872A1 (ru) Способ получения бензоксаборолов
CL2021000171A1 (es) Procedimiento y productos intermedios para la preparación de bilastina
UY39789A (es) Intermedio novedoso para la preparación de piroxasulfona.
PE20191103A1 (es) Inhibidores de dopamina-b-hidroxilasa
PA8650401A1 (es) Sintesis asimetrica de dihidrobenzofuranos sustituidos